表紙:水疱性角膜症治療の世界市場-2023年~2030年
市場調査レポート
商品コード
1374786

水疱性角膜症治療の世界市場-2023年~2030年

Global Bullous Keratopathy Treatment Market -2023-2030

出版日: | 発行: DataM Intelligence | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.11円
水疱性角膜症治療の世界市場-2023年~2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

水疱性角膜症は角膜浮腫とも呼ばれ、角膜内皮が角膜の正常な透明性と脱水状態を維持できないために生じる角膜の腫脹によって引き起こされます。ほとんどの場合、角膜内皮ジストロフィーまたは角膜内皮外傷が原因です。腫脹により、角膜表面に液体を含んだ水疱が形成されます。明るい光を見ると過敏になり、視界が著しくぼやけます。

水疱性角膜症の治療には、高張食塩水の点眼や軟膏、クリアな視界を得るためのコンタクトレンズ、ステロイド薬、角膜移植と呼ばれる手術などがあります。角膜から余分な液体を出すために、塩分を含んだ点眼薬(高張食塩水)や塩分を含んだ軟膏(高張塩化ナトリウム)を使用します。ソフトコンタクトレンズを短期間使用し、角膜を包帯のように覆うことで不快感を軽減することもあります。視力が低下したり、不快感が大きく長期化する場合は、角膜移植が行われることが多いです。

市場力学:促進要因

治療イノベーションに対する需要の増加

水疱性角膜症の治療に対する技術革新への需要の高まりが、予測期間中の市場を牽引すると予想されます。水疱性角膜症に対する既存の治療法の有効性が限定的であったり、重大な副作用を伴う場合、新しく改良された治療法の開発に対する強い動機付けとなります。このようなアンメット・メディカル・ニーズは、市場への投資と技術革新を刺激する可能性があります。

例えば、2023年3月、日本の独立行政法人医薬品医療機器総合機構(PMDA)は、水疱性角膜症患者の治療薬として、オーリオン・バイオテックの同種細胞治療薬Vyznovaを承認しました。この承認は、角膜内皮疾患に対する同種細胞治療としては初めてと思われます。

さらに、炎症性筋炎の治療でより良い結果を示す新規治療薬の開発に向けて、多くの臨床試験が進行中です。例えば、2023年6月には、Trefoil Therapeutics社が角膜浮腫を経験した患者の予後改善に取り組んでいます。トレフォイル社が開発したTTHX1114と呼ばれる新しい治験治療薬は、角膜細胞を損傷から守り、それらの組織の治癒速度を改善する自然な細胞プロセスを刺激することが示されています。

さらに、水疱性角膜症の有病率の増加、臨床試験の新興国市場の拡大、新規薬剤や治療法の開発における認知度の向上と進歩は、予測期間中に市場を牽引すると予想される要因です。

阻害要因

コンタクトレンズ、ステロイド、手術に伴う合併症、水疱性角膜症の治療にかかる高額な費用、治療に対する認識不足などの要因が市場を阻害すると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 治療イノベーションに対する需要の増加
    • 抑制要因
      • 手術費用の高騰
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • 特許分析
  • ボリューム分析
  • DMIオピニオン

第6章 COVID-19分析

第7章 疾患タイプ別

  • 偽水疱性水疱性角膜症
  • 無水晶体水疱性角膜症

第8章 治療タイプ別

  • 高張食塩水の点眼と軟膏
  • コンタクトレンズ
  • ステロイド
  • 角膜移植
  • その他

第9章 販売チャネル別

  • 販売チャネル
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • エンドユーザー
    • 病院
    • 眼科クリニック
    • 外来手術センター
    • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Alcon Vision LLC
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • CooperVision, Inc.
  • Bausch & Lomb Inc.
  • Johnson and Johnson
  • Grevis Pharmaceuticals Pvt Ltd
  • Rayner Group
  • SERVIMED INDUSTRIAL S.P.A.
  • MERCK & CO., Inc.
  • AbbVie Inc.
  • Novartis AG

第13章 付録

目次
Product Code: PH7195

Overview

Bullous keratopathy is also known as corneal edema caused by swelling of the cornea, resulting from the failure of the corneal endothelium to maintain the normally transparent, dehydrated state of the cornea. Most frequently, it is due to corneal endothelial dystrophy or corneal endothelial trauma. The swelling leads to the formation of fluid-filled blisters on the surface of the cornea. Sensitivity when looking at bright lights and significant blurring of vision can result.

The treatment of bullous keratopathy includes hypertonic saline drops and ointments, contact lenses for clear vision, steroid drugs, surgery called corneal transplantation and other treatments. Salty eye drops (hypertonic saline) and salty ointments (hypertonic sodium chloride) are used to draw the excess fluid from the cornea. On occasion, soft contact lenses can be used for a short period of time to decrease discomfort by acting as a bandage to the cornea. If vision is reduced or discomfort is significant and prolonged, corneal transplantation is often done.

Market Dynamics: Drivers

Increasing demand for therapeutic innovations

The increasing demand for therapeutic innovations for the treatment of bullous keratopathy is expected to drive the market over the forecast period. If the existing treatments for bullous keratopathy are limited in their effectiveness or are associated with significant side effects, there is a strong incentive for the development of new and improved therapies. This unmet medical need can stimulate investment and innovation in the market.

For instance, in March 2023, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved Aurion Biotech's allogeneic cell therapy, Vyznova, to treat patients with bullous keratopathy. This approval is believed to be the first for an allogeneic cell therapy for corneal endothelial disease.

Moreover, many clinical trials are going on for the development of novel therapeutics that show better results in inflammatory myositis treatment. For instance, in June 2023, Trefoil Therapeutics is working to improve outcomes in patients who experience corneal edema. A new investigational therapy developed by Trefoil, called TTHX1114, has been shown to stimulate natural cellular processes that protect the corneal cells from damage and improve the rate at which those tissues heal.

Further, the increasing prevalence of bullous keratopathy, increasing clinical trials, increasing awareness and advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with contact lenses, steroids and surgery, the high cost of the treatment of bullous keratopathy and the lack of awareness about the treatment are expected to hamper the market.

Segment Analysis

The global bullous keratopathy treatment market is segmented based on disease type, treatment type, sales channel and region.

The hypertonic saline drops and ointments segment accounted for approximately 57.3% of the bullous keratopathy treatment market share

The hypertonic saline drops and ointments segment is expected to hold the largest market share over the forecast period. These are considered as a first-line treatment for the bullous keratopathy. These are often used to reduce corneal edema and alleviate discomfort. Hypertonic saline drops are occasionally used to draw excess fluid from the cornea

For instance, according to the National Institute of Health, topical ocular hypertonic saline seems to be a safe and effective treatment in the management of less severe forms of corneal edema or bullous keratopathy and other corneal disorders such as filamentary keratitis.

Further, hypertonic saline solutions have a higher salt concentration than the natural tears in the eye. When applied topically, they create an osmotic gradient, drawing excess fluid out of the cornea. This helps to reduce corneal edema and relieve the associated pain and discomfort. The primary goal of using hypertonic saline drops and ointments in bullous keratopathy is to alleviate the symptoms, such as pain, photophobia and blurred vision, which are caused by the presence of corneal bullae.

Geographical Analysis

North America accounted for approximately 38.5% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials and research activities, which leads to the launch of innovative treatments.

Furthermore, the presence of advanced healthcare facilities, state-of-the-art medical technology, and highly trained healthcare professionals can significantly impact the bullous keratopathy treatment market. The advanced facilities in the region helps to treat the patients with better patient outcomes by using the advanced technologies.

Competitive Landscape

The major global players in the bullous keratopathy treatment market include: Alcon Vision LLC, CooperVision, Inc., Bausch & Lomb Inc., Johnson and Johnson, Grevis Pharmaceuticals Pvt Ltd, Rayner Group, SERVIMED INDUSTRIAL S.P.A., MERCK & CO., Inc., AbbVie Inc., Novartis AG and among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global bullous keratopathy treatment market. During the initial phases of the pandemic, healthcare systems faced tremendous pressure to respond to the surge in COVID-19 cases globally. This results in many elective medical procedures, including non-urgent eye surgeries, being postponed or canceled. This led to delays in the treatment of bullous keratopathy. The pandemic also disrupted the supply chain of these treatment drugs globally.

Why Purchase the Report?

  • To visualize the global bullous keratopathy treatment market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of bullous keratopathy treatment market-level with all segments
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
  • Product mapping available as excel consisting of key products of all the major players

The global bullous keratopathy treatment market report would provide approximately 61 tables, 57 figures, and 187 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by Sales Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Therapeutic Innovations
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of the Surgery
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. Volume Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Pseudophakic Bullous Keratopathy*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Aphakic Bullous Keratopathy

8. By Treatment Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.1.2. Market Attractiveness Index, By Treatment Type
  • 8.2. Hypertonic Saline Drops and Ointments*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Contact Lenses
  • 8.4. Steroids
  • 8.5. Corneal Transplantation
  • 8.6. Others

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 9.1.2. Market Attractiveness Index, By Sales Channel
  • 9.2. Distribution Channel*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 9.2.3. Hospital Pharmacies
    • 9.2.4. Retail Pharmacies
    • 9.2.5. Online Pharmacies
  • 9.3. End-User
    • 9.3.1. Hospitals
    • 9.3.2. Ophthalmic Clinics
    • 9.3.3. Ambulatory Surgical Centers
    • 9.3.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Alcon Vision LLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. CooperVision, Inc.
  • 12.3. Bausch & Lomb Inc.
  • 12.4. Johnson and Johnson
  • 12.5. Grevis Pharmaceuticals Pvt Ltd
  • 12.6. Rayner Group
  • 12.7. SERVIMED INDUSTRIAL S.P.A.
  • 12.8. MERCK & CO., Inc.
  • 12.9. AbbVie Inc.
  • 12.10. Novartis AG

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us